Publicaciones en colaboración con investigadoras/es de Instituto de Investigación Sanitaria Biobizkaia (19)

2024

  1. Medication impact on oral health in schizophrenia

    Medicina Oral Patologia Oral y Cirugia Bucal, Vol. 29, Núm. 1, pp. e51-e57

2023

  1. Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database

    European Journal of Clinical Pharmacology, Vol. 79, Núm. 5, pp. 679-685

  2. Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment

    International Review of Neurobiology (Academic Press Inc.), pp. 103-143

2022

  1. Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation

    Frontiers in Pharmacology, Vol. 13

  2. Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis

    Parkinsonism and Related Disorders, Vol. 99, pp. 107-115

  3. Preferential Modulatory Action of 5-HT2A Receptors on the Dynamic Regulation of Basal Ganglia Circuits

    Journal of Neuroscience, Vol. 43, Núm. 1, pp. 56-67

2021

  1. Antipsychotics as environmental pollutants: An underrated threat?

    Science of the Total Environment, Vol. 769

  2. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study

    European Neuropsychopharmacology, Vol. 50, pp. 107-111

  3. Dopaminergic denervation impairs cortical motor and associative/limbic information processing through the basal ganglia and its modulation by the CB1 receptor

    Neurobiology of Disease, Vol. 148

  4. Prophylactic laxatives in clozapine-treated patients: A long road ahead

    Revista de Psiquiatria Clinica, Vol. 48, Núm. 1, pp. 66-68

  5. Study of tissue-specific reactive oxygen species formation by cell membrane microarrays for the characterization of bioactive compounds

    Membranes, Vol. 11, Núm. 12

2020

  1. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

  2. The Noradrenergic System in Parkinson’s Disease

    Frontiers in Pharmacology, Vol. 11

2019

  1. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats

    Experimental Neurology, Vol. 322

  2. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation

    Neurobiology of Disease, Vol. 121, pp. 252-262

  3. Cannabinoids differentially modulate cortical information transmission through the sensorimotor or medial prefrontal basal ganglia circuits

    British Journal of Pharmacology, Vol. 176, Núm. 8, pp. 1156-1169

  4. Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model

    European Neuropsychopharmacology, Vol. 29, Núm. 5, pp. 590-600

  5. Environmental enrichment shapes striatal spike-timing-dependent plasticity in vivo

    Scientific Reports, Vol. 9, Núm. 1

  6. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders

    International Review of Neurobiology (Academic Press Inc.), pp. 229-257